A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Zai Lab LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 17,300 shares of ZLAB stock, worth $453,779. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,300
Previous 8,000 116.25%
Holding current value
$453,779
Previous $138,000 202.17%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.25 - $24.14 $7.1 Million - $10.5 Million
436,706 Added 48.54%
1,336,372 $32.3 Million
Q2 2024

Aug 14, 2024

BUY
$13.72 - $21.55 $3.28 Million - $5.15 Million
239,092 Added 36.19%
899,666 $15.6 Million
Q1 2024

May 15, 2024

BUY
$15.95 - $26.8 $10 Million - $16.9 Million
629,984 Added 2059.44%
660,574 $10.6 Million
Q4 2023

Feb 14, 2024

SELL
$22.97 - $30.58 $2.52 Million - $3.35 Million
-109,615 Reduced 78.18%
30,590 $836,000
Q3 2023

Nov 14, 2023

SELL
$22.72 - $31.49 $1.43 Million - $1.99 Million
-63,126 Reduced 31.05%
140,205 $3.41 Million
Q2 2023

Aug 14, 2023

BUY
$25.3 - $39.67 $3.93 Million - $6.16 Million
155,313 Added 323.45%
203,331 $5.64 Million
Q1 2023

May 15, 2023

BUY
$30.21 - $48.1 $834,823 - $1.33 Million
27,634 Added 135.57%
48,018 $1.6 Million
Q4 2022

Feb 14, 2023

BUY
$22.28 - $38.71 $454,155 - $789,064
20,384 New
20,384 $625,000
Q2 2022

Aug 15, 2022

BUY
$23.14 - $49.68 $684,110 - $1.47 Million
29,564 Added 59.75%
79,043 $2.74 Million
Q4 2021

Feb 14, 2022

SELL
$54.9 - $105.21 $5.04 Million - $9.66 Million
-91,853 Reduced 64.99%
49,479 $3.11 Million
Q3 2021

Nov 15, 2021

BUY
$105.0 - $178.37 $12.3 Million - $20.9 Million
117,099 Added 483.22%
141,332 $14.9 Million
Q2 2021

Aug 16, 2021

SELL
$125.11 - $180.0 $1.28 Million - $1.84 Million
-10,198 Reduced 29.62%
24,233 $4.29 Million
Q1 2021

May 17, 2021

BUY
$126.27 - $191.71 $4.09 Million - $6.2 Million
32,366 Added 1567.36%
34,431 $4.59 Million
Q4 2020

Feb 16, 2021

SELL
$81.94 - $135.34 $141,838 - $234,273
-1,731 Reduced 45.6%
2,065 $279,000
Q3 2020

Nov 16, 2020

SELL
$73.3 - $89.48 $872,343 - $1.06 Million
-11,901 Reduced 75.82%
3,796 $316,000
Q2 2020

Aug 14, 2020

SELL
$48.82 - $82.53 $2.37 Million - $4 Million
-48,471 Reduced 75.54%
15,697 $1.29 Million
Q4 2019

Feb 14, 2020

SELL
$29.79 - $43.06 $175,194 - $253,235
-5,881 Reduced 8.4%
64,168 $2.67 Million
Q3 2019

Nov 14, 2019

BUY
$30.47 - $37.65 $1.05 Million - $1.3 Million
34,572 Added 97.45%
70,049 $2.27 Million
Q2 2019

Aug 14, 2019

BUY
$25.73 - $35.79 $386,927 - $538,210
15,038 Added 73.58%
35,477 $1.24 Million
Q1 2019

May 15, 2019

BUY
$21.71 - $31.54 $73,054 - $106,132
3,365 Added 19.71%
20,439 $0
Q3 2018

Nov 13, 2018

BUY
$17.8 - $25.35 $303,917 - $432,825
17,074 New
17,074 $0

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.57B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.